Der Kardiologe

, Volume 5, Issue 2, pp 129–144 | Cite as

Einsatz von neuen Antikoagulanzien bei kardiovaskulären Erkrankungen

CME Weiterbildung · Zertifizierte Fortbildung
  • 127 Downloads

Zusammenfassung

Neben einer Steigerung der Effektivität gilt eine gleichzeitige Senkung des Blutungsrisikos als Voraussetzung für neue Antikoagulanzien im Bereich der kardiovaskulären Medizin. Durch eben diese Eigenschaften schafften es der anti-Xa-Inhibitor Fondaparinux und das direkte Antithrombin Bivalirudin, in die internationalen Leitlinien zur Behandlung des akuten Koronarsyndroms aufgenommen zu werden, und haben hier einen bedeutsamen Stellenwert neben den Heparinen erlangt. Andere Substanzen stehen kurz vor der Einführung in die klinische Routine, wie etwa das oral verfügbare Antithrombin Dabigatran für Patienten mit Vorhofflimmern. Anti-Xa-Inhibitoren wie Rivaroxaban und Apixapan werden in der Indikation des akuten Koronarsyndroms wie auch bei Vorhofflimmern geprüft. Die vorliegende Arbeit versucht die aktuellen Erkenntnisse zu den neuen Antikoagulanzien dem Leser übersichtlich vorzustellen.

Schlüsselwörter

Antikoagulanzien Kardiovaskuläre Erkrankungen Blutungsrisiko Anti-Xa-Inhibitor Direktes Antithrombin 

Use of new anticoagulants for cardiovascular diseases

Abstract

Apart from higher efficacy a lower risk of bleeding has become the main target for the development of new anticoagulants in cardiovascular medicine. Due to these characteristics the anti-Xa inhibitor fondaparinux as well as the direct antithrombin bivalirudin have been included in the updated international guidelines for the therapy of patients with acute coronary syndromes. Other anti-Xa inhibitors, e.g. apixapan and rivaroxaban, are still in the field of investigation. Moreover, the new direct antithrombin dabigatran will be used for anticoagulation in atrial fibrillation and has become the primary alternative medication to vitamin K antagonists. This review tries to introduce the most important new anticoagulants by presenting current study results.

Keywords

Anticoagulants Cardiovascular diseases Risk of bleeding Anti-Xa inhibitor Direct antithrombin 

Notes

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Bassand JP, Hamm CW, Ardissino D et al (2007) Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28:1598–1660PubMedCrossRefGoogle Scholar
  2. 2.
    Antman EM, McCabe CH, Gurfinkel EP et al (1999) Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 100:1593–1601PubMedGoogle Scholar
  3. 3.
    Cohen M, Demers C, Gurfinkel EP et al (1998) Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and safety of subcutaneous enoxaparin versus intravenous unfractionated heparin, in non-Q-wave coronary events. Am J Cardiol 82:19L–24LPubMedCrossRefGoogle Scholar
  4. 4.
    Gibson CM, Murphy SA, Montalescot G et al (2007) Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 49:2238–2246PubMedCrossRefGoogle Scholar
  5. 5.
    Anderson JL, Adams CD, Antman EM et al (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50:e1–e157PubMedCrossRefGoogle Scholar
  6. 6.
    Antman EM, Hand M, Armstrong PW et al (2008) 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 117:296–329PubMedCrossRefGoogle Scholar
  7. 7.
    Van de Werf F, Bax J, Betriu A et al (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 29:2909–2945CrossRefGoogle Scholar
  8. 8.
    The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators (1990) The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 323:1505–1511CrossRefGoogle Scholar
  9. 9.
    Stroke prevention in Atrial Fibrillation Investigators (1991) Stroke prevention in Atrial Fibrillation Study. Final results. Circulation 84:527–539Google Scholar
  10. 10.
    Ezekowitz MD, Bridgers SL, James KE et al (1992) Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 327:1406–1412PubMedCrossRefGoogle Scholar
  11. 11.
    Petersen P, Boysen G, Godtfredsen J et al (1989) Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1:175–179PubMedCrossRefGoogle Scholar
  12. 12.
    Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151PubMedCrossRefGoogle Scholar
  13. 13.
    Chew DP, Bhatt DL, Kimball W et al (2003) Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol 92:919–923PubMedCrossRefGoogle Scholar
  14. 14.
    Becker DL, Fredenburgh JC, Stafford AR, Weitz JI (1999) Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II. J Biol Chem 274:6226–6233PubMedCrossRefGoogle Scholar
  15. 15.
    Brieger DB, Mak KH, Kottke-Marchant K, Topol EJ (1998) Heparin-induced thrombocytopenia. J Am Coll Cardiol 31:1449–1459PubMedCrossRefGoogle Scholar
  16. 16.
    Bittl JA, Chaitman BR, Feit F et al (2001) Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 142:952–959PubMedCrossRefGoogle Scholar
  17. 17.
    Bittl JA, Strony J, Brinker JA et al (1995) Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 333:764–769PubMedCrossRefGoogle Scholar
  18. 18.
    Lincoff AM, Bittl JA, Harrington RA et al (2003) Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289:853–863PubMedCrossRefGoogle Scholar
  19. 19.
    Stone GW, McLaurin BT, Cox DA et al (2006) Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355:2203–2216PubMedCrossRefGoogle Scholar
  20. 20.
    Stone GW, Ware JH, Bertrand ME et al (2007) Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA 298:2497–2506PubMedCrossRefGoogle Scholar
  21. 21.
    Stone GW, Witzenbichler B, Guagliumi G et al (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358:2218–2230PubMedCrossRefGoogle Scholar
  22. 22.
    Mehran R, Lansky AJ, Witzenbichler B et al (2009) Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 374:1149–1159PubMedCrossRefGoogle Scholar
  23. 23.
    Turpie AG (2004) Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy. Expert Opin Pharmacother 5:1373–1384PubMedCrossRefGoogle Scholar
  24. 24.
    Spinler SA (2006) New concepts in heparin-induced thrombocytopenia: diagnosis and management. J Thromb Thrombolysis 21:17–21PubMedCrossRefGoogle Scholar
  25. 25.
    Lobo B, Finch C, Howard A, Minhas S (2008) Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 99:208–214PubMedGoogle Scholar
  26. 26.
    Warkentin TE (2008) Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT) – bridging the River Coumarin. Thromb Haemost 99:2–3PubMedGoogle Scholar
  27. 27.
    Handschin AE, Trentz OA, Hoerstrup SP et al (2005) Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Br J Surg 92:177–183PubMedCrossRefGoogle Scholar
  28. 28.
    Simoons ML, Bobbink IW, Boland J et al (2004) A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) study. J Am Coll Cardiol 43:2183–2190PubMedCrossRefGoogle Scholar
  29. 29.
    Yusuf S, Mehta SR, Chrolavicius S et al (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354:1464–1476PubMedCrossRefGoogle Scholar
  30. 30.
    Coussement PK, Bassand JP, Convens C et al (2001) A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 22:1716–1724PubMedCrossRefGoogle Scholar
  31. 31.
    Yusuf S, Mehta SR, Chrolavicius S et al (2006) Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295:1519–1530PubMedCrossRefGoogle Scholar
  32. 32.
    Kubitza D, Becka M, Voith B et al (2005) Safety, pharmacodynamics and pharmacokinetics of single doses of BAY 59–7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78:412–421PubMedCrossRefGoogle Scholar
  33. 33.
    Kubitza D, Becka M, Wensing G et al (2005) Safety, pharmacodynamics and pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61:873–880PubMedCrossRefGoogle Scholar
  34. 34.
    Kubitza D, Becka M, Mueck W, Zuehlsdorf M (2006) Safety, tolerability, pharmacodynamics and pharmacokinetics of rivaroxaban – an oral, direct factor Xa inhibitor – are not affected by aspirin. J Clin Pharmacol 46:981–990PubMedCrossRefGoogle Scholar
  35. 35.
    Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2006) Effect of food, an antacid and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 46:549–558PubMedCrossRefGoogle Scholar
  36. 36.
    Mega JL, Braunwald E, Mohanavelu S et al (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374:29–38PubMedCrossRefGoogle Scholar
  37. 37.
    Alexander JH, Becker RC, Bhatt DL et al (2009) Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 119:2877–2885PubMedCrossRefGoogle Scholar
  38. 38.
    Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692–694PubMedCrossRefGoogle Scholar
  39. 39.
    Cohen M, Bhatt DL, Alexander JH et al (2007) Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation 115:2642–2651PubMedCrossRefGoogle Scholar
  40. 40.
    Sabatine MS, Antman EM, Widimsky P et al (2009) Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet 374:787–795PubMedCrossRefGoogle Scholar
  41. 41.
    Wallentin L, Wilcox RG, Weaver WD et al (2003) Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 362:789–797PubMedCrossRefGoogle Scholar
  42. 42.
    Albers GW, Diener HC, Frison L et al (2005) Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 293:690–698PubMedCrossRefGoogle Scholar
  43. 43.
    Albers GW (2004) Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials. Am J Manag Care 10:S462–S469; discussion S469–S473PubMedGoogle Scholar
  44. 44.
    Olsson SB (2003) Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362:1691–1698PubMedCrossRefGoogle Scholar
  45. 45.
    Stangier J (2008) Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 47:285–295PubMedCrossRefGoogle Scholar
  46. 46.
    Ezekowitz MD, Reilly PA, Nehmiz G et al (2007) Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study). Am J Cardiol 100:1419–1426PubMedCrossRefGoogle Scholar
  47. 47.
    Connolly S, Pogue J, Hart R et al (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367:1903–1912PubMedCrossRefGoogle Scholar
  48. 48.
    Rao SV, O’Grady K, Pieper KS et al (2005) Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 96:1200–1206PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.3. Medizinische Abteilung mit Kardiologie und Internistischer NotaufnahmeWilhelminenspitalWienÖsterreich
  2. 2.2. Universitätsklinik für Innere Medizin mit Kardiologie und AngiologieMedizinische Universität WienWienÖsterreich

Personalised recommendations